{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T21:33:06Z","timestamp":1793309586147,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100011033","name":"Thermo Fisher Scientific Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011033","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.jpba.2026.117749","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:49:25Z","timestamp":1790264965000},"page":"117749","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Compliance-ready workflow for antisense oligonucleotide impurity analysis without ion pairing agents"],"prefix":"10.1016","volume":"283","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5350-9132","authenticated-orcid":false,"given":"Silvia","family":"Mill\u00e1n-Mart\u00edn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrik H.","family":"Mistarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4565-7359","authenticated-orcid":false,"given":"Felipe","family":"Guapo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5943-8993","authenticated-orcid":false,"given":"Sara","family":"Carillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5176-7736","authenticated-orcid":false,"given":"Ken","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Bones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2026.117749_bib1","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1146\/annurev-neuro-070918-050501","article-title":"Antisense oligonucleotide therapies for neurodegenerative diseases","volume":"42","author":"Bennett","year":"2019","journal-title":"Annu. Rev. Neurosci."},{"issue":"7","key":"10.1016\/j.jpba.2026.117749_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22073295","article-title":"Recent advances in oligonucleotide therapeutics in oncology","volume":"22","author":"Xiong","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jpba.2026.117749_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2023.1250276","article-title":"Nucleic acid-based therapeutics for the treatment of central nervous system disorders","volume":"14","author":"McCartan","year":"2023","journal-title":"Front. Genet."},{"issue":"2","key":"10.1016\/j.jpba.2026.117749_bib4","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1089\/nat.2023.0068","article-title":"Nucleic acid therapeutics: successes, milestones, and upcoming innovation","volume":"34","author":"Belgrad","year":"2024","journal-title":"Nucleic Acid. Ther."},{"issue":"11","key":"10.1016\/j.jpba.2026.117749_bib5","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1080\/17425255.2021.1992382","article-title":"Antisense oligonucleotides: absorption, distribution, metabolism, and excretion","volume":"17","author":"Shadid","year":"2021","journal-title":"Expert. Opin. Drug. Metab. Toxicol."},{"issue":"6","key":"10.1016\/j.jpba.2026.117749_bib6","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1093\/nar\/gkad067","article-title":"Chemistry, structure and function of approved oligonucleotide therapeutics","volume":"51","author":"Egli","year":"2023","journal-title":"Nucleic Acids Res."},{"issue":"3","key":"10.1016\/j.jpba.2026.117749_bib7","doi-asserted-by":"crossref","first-page":"241","DOI":"10.4062\/biomolther.2023.001","article-title":"Drug discovery perspectives of antisense oligonucleotides","volume":"31","author":"Kim","year":"2023","journal-title":"Biomol. Ther. (Seoul)"},{"issue":"7","key":"10.1016\/j.jpba.2026.117749_bib8","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.ymthe.2017.03.013","article-title":"Lipid nanoparticle systems for enabling gene therapies","volume":"25","author":"Cullis","year":"2017","journal-title":"Mol. Ther."},{"issue":"2","key":"10.1016\/j.jpba.2026.117749_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14020342","article-title":"Delivery of oligonucleotides: efficiency with lipid conjugation and clinical outcome","volume":"14","author":"Tran","year":"2022","journal-title":"Pharmaceutics"},{"issue":"13","key":"10.1016\/j.jpba.2026.117749_bib10","doi-asserted-by":"crossref","first-page":"8796","DOI":"10.1093\/nar\/gku531","article-title":"Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice","volume":"42","author":"Prakash","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jpba.2026.117749_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2025.465968","article-title":"Impact of nucleotide hydrophobicity on oligonucleotides separation in liquid chromatography","volume":"1753","author":"Gilar","year":"2025","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jpba.2026.117749_bib12","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10337-023-04291-y","article-title":"HPLC retention behavior of oligonucleotides on an anion-exchange HPLC with a high concentration of urea","volume":"87","author":"Kawamura","year":"2024","journal-title":"Chromatographia"},{"issue":"10","key":"10.1016\/j.jpba.2026.117749_bib13","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.4155\/bio.11.66","article-title":"Advantages of ion-exchange chromatography for oligonucleotide analysis","volume":"3","author":"Cook","year":"2011","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jpba.2026.117749_bib14","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.chroma.2016.02.057","article-title":"Nucleic acid separations using superficially porous silica particles","volume":"1440","author":"Close","year":"2016","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jpba.2026.117749_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2025.466550","article-title":"Current trends in liquid chromatography-mass spectrometry analysis of small interfering RNAs: a short review","volume":"1766","author":"Togawa","year":"2026","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jpba.2026.117749_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2020.113105","article-title":"Characterization of therapeutic oligonucleotides by liquid chromatography","volume":"182","author":"Goyon","year":"2020","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"23-24","key":"10.1016\/j.jpba.2026.117749_bib17","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1007\/s10337-014-2766-x","article-title":"The effects of stationary phases on retention and selectivity of oligonucleotides in IP-RP-HPLC","volume":"77","author":"Studzinska","year":"2014","journal-title":"Chromatographia"},{"key":"10.1016\/j.jpba.2026.117749_bib18","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jpba.2017.02.014","article-title":"The impact of ion-pairing reagents on the selectivity and sensitivity in the analysis of modified oligonucleotides in serum samples by liquid chromatography coupled with tandem mass spectrometry","volume":"138","author":"Studzinska","year":"2017","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117749_bib19","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jpba.2016.12.036","article-title":"Evaluation of size-exclusion chromatography for the analysis of phosphorothioate oligonucleotides","volume":"136","author":"Shimoyama","year":"2017","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"24","key":"10.1016\/j.jpba.2026.117749_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232415474","article-title":"Bioanalysis of oligonucleotide by LC-MS: effects of ion pairing regents and recent advances in ion-pairing-free analytical strategies","volume":"23","author":"Liu","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jpba.2026.117749_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2020.461100","article-title":"Application of hydrophilic interaction liquid chromatography coupled with tandem mass spectrometry for the retention and sensitivity studies of antisense oligonucleotides","volume":"1622","author":"Kilanowska","year":"2020","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jpba.2026.117749_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2024.465378","article-title":"Current state of hydrophilic interaction liquid chromatography of oligonucleotides","volume":"1736","author":"Bartlett","year":"2024","journal-title":"J. Chromatogr. A"},{"issue":"9","key":"10.1016\/j.jpba.2026.117749_bib23","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1021\/jasms.4c00270","article-title":"Overcoming challenges in oligonucleotide therapeutics analysis: a novel nonion pair approach","volume":"35","author":"Hayashi","year":"2024","journal-title":"J. Am. Soc. Mass. Spectrom."},{"key":"10.1016\/j.jpba.2026.117749_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2026.117546","article-title":"Hydrophilic interaction chromatography and tandem mass spectrometry for the characterization of methylated oligoribonucleotides","volume":"278","author":"Adouairi","year":"2026","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117749_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2021.462184","article-title":"Analytical characterization of DNA and RNA oligonucleotides by hydrophilic interaction liquid chromatography-tandem mass spectrometry","volume":"1648","author":"Huang","year":"2021","journal-title":"J. Chromatogr. A"},{"issue":"117758","key":"10.1016\/j.jpba.2026.117749_bib26","first-page":"1","article-title":"Recent advances and current challenges in hydrophilic interaction chromatography for the analysis of therapeutic oligonucleotides","volume":"117758","author":"Lardeux","year":"2024","journal-title":"Trends Anal. Chem."},{"key":"10.1016\/j.jpba.2026.117749_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2026.467085","article-title":"Ion-pair-free reversed-phase liquid chromatographic profiling of oligonucleotides through selective phosphorothioate alkylation","volume":"1781","author":"Bui","year":"2026","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jpba.2026.117749_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2025.466517","article-title":"Rapid and flexible analytical characterization of oligonucleotides in early drug discovery","volume":"1765","author":"Stavenhagen","year":"2026","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jpba.2026.117749_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2024.465380","article-title":"Separation and identification of oligonucleotides impurities and degradation products by reversed phase ultra-high performance liquid chromatography using phenyl-bonded stationary phases without ion pairs - a step towards sustainability","volume":"1736","author":"Studzinska","year":"2024","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jpba.2026.117749_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2025.466395","article-title":"Systematic evaluation of phenyl stationary phases for oligonucleotide analysis without ion-pairing reagents","volume":"1762","author":"Tsalmpouris","year":"2025","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jpba.2026.117749_bib31","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ab.2018.06.019","article-title":"Two-dimensional liquid chromatography-mass spectrometry for the characterization of modified oligonucleotide impurities","volume":"556","author":"Roussis","year":"2018","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.jpba.2026.117749_bib32","unstructured":"EMA\/CHMP\/CVMP\/QWP\/262313\/202424, Development and manufacture of oligonucleotides - Scientific guideline, (2024)."},{"issue":"3","key":"10.1016\/j.jpba.2026.117749_bib33","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1089\/nat.2021.0056","article-title":"Assay, purity, and impurity profile of phosphorothioate oligonucleotide therapeutics by ion pair-HPLC-MS","volume":"32","author":"Rentel","year":"2022","journal-title":"Nucleic Acid. Ther."},{"key":"10.1016\/j.jpba.2026.117749_bib34","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jpba.2019.05.012","article-title":"Determination of oligonucleotide deamination by high resolution mass spectrometry","volume":"173","author":"Rentel","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"12","key":"10.1016\/j.jpba.2026.117749_bib35","doi-asserted-by":"crossref","first-page":"7448","DOI":"10.1021\/acs.est.2c00321","article-title":"The next frontier of environmental unknowns: substances of unknown or variable composition, complex reaction products, or biological materials (UVCBs)","volume":"56","author":"Lai","year":"2022","journal-title":"Environ. Sci. Technol."},{"key":"10.1016\/j.jpba.2026.117749_bib36","article-title":"Validation of Analytical Procedures Q2(R2)","author":"ICH","year":"2022","journal-title":"ICH Harmonised Tripartite Guideline, International Council for Harmonisation (ICH)"},{"issue":"117097","key":"10.1016\/j.jpba.2026.117749_bib37","first-page":"1","article-title":"Characterisation of small RNA-based therapeutics and their process impurities by fast and sensitive liquid chromatography high resolution mass spectrometry","volume":"268","author":"Mill\u00e1n-Mart\u00edn","year":"2026","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"24","key":"10.1016\/j.jpba.2026.117749_bib38","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1002\/rcm.7409","article-title":"Comparing ion-pairing reagents and counter anions for ion-pair reversed-phase liquid chromatography\/electrospray ionization mass spectrometry analysis of synthetic oligonucleotides","volume":"29","author":"Gong","year":"2015","journal-title":"Rapid Commun. Mass. Spectrom."},{"issue":"13","key":"10.1016\/j.jpba.2026.117749_bib39","doi-asserted-by":"crossref","DOI":"10.1002\/rcm.10033","article-title":"Optimisation of heated electrospray ionisation parameters to minimise in-source generated impurities in the analysis of oligonucleotide therapeutics","volume":"39","author":"Glenister","year":"2025","journal-title":"Rapid Commun. Mass. Spectrom."},{"key":"10.1016\/j.jpba.2026.117749_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2022.462839","article-title":"Development of an ion pairing reversed-phase liquid chromatography-mass spectrometry method for characterization of clustered regularly interspaced short palindromic repeats guide ribonucleic acid","volume":"1665","author":"Wei","year":"2022","journal-title":"J. Chromatogr. A"}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708526004176?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708526004176?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T21:26:21Z","timestamp":1793309181000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708526004176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":40,"alternative-id":["S0731708526004176"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2026.117749","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Compliance-ready workflow for antisense oligonucleotide impurity analysis without ion pairing agents","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2026.117749","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117749"}}